Immutep Valuation

Is IMM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IMM (A$0.3) is trading below our estimate of fair value (A$8.07)

Significantly Below Fair Value: IMM is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMM?

Other financial metrics that can be useful for relative valuation.

IMM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue80.9x
Enterprise Value/EBITDA-7.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does IMM's PB Ratio compare to its peers?

The above table shows the PB ratio for IMM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average46.9x
IMU Imugene
2.2x50.7%AU$418.9m
MSB Mesoblast
1.7x48.8%AU$1.3b
CUV Clinuvel Pharmaceuticals
4.4x26.8%AU$777.7m
DXB Dimerix
179.5xn/aAU$308.1m
IMM Immutep
3.6x40.1%AU$420.2m

Price-To-Book vs Peers: IMM is good value based on its Price-To-Book Ratio (3.6x) compared to the peer average (46.9x).


Price to Earnings Ratio vs Industry

How does IMM's PE Ratio compare vs other companies in the AU Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No more companies

Price-To-Book vs Industry: IMM is expensive based on its Price-To-Book Ratio (3.6x) compared to the Australian Biotechs industry average (3.4x).


Price to Book Ratio vs Fair Ratio

What is IMM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IMM's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.29
AU$0.98
+230.8%
13.9%AU$1.13AU$0.75n/a5
Jul ’25AU$0.31
AU$0.94
+203.9%
12.8%AU$1.13AU$0.75n/a5
Jun ’25AU$0.45
AU$0.98
+117.3%
10.4%AU$1.10AU$0.80n/a5
May ’25AU$0.42
AU$0.98
+132.9%
10.4%AU$1.10AU$0.80n/a5
Apr ’25AU$0.38
AU$1.30
+241.1%
62.1%AU$2.88AU$0.65n/a5
Mar ’25AU$0.35
AU$1.28
+264.6%
64.4%AU$2.88AU$0.55n/a5
Feb ’25AU$0.34
AU$1.28
+275.3%
64.4%AU$2.88AU$0.55n/a5
Jan ’25AU$0.34
AU$1.26
+264.1%
65.9%AU$2.88AU$0.55n/a5
Dec ’24AU$0.30
AU$1.26
+318.7%
65.9%AU$2.88AU$0.55n/a5
Nov ’24AU$0.32
AU$1.26
+298.7%
65.9%AU$2.88AU$0.55n/a5
Oct ’24AU$0.28
AU$1.26
+348.6%
65.9%AU$2.88AU$0.55n/a5
Sep ’24AU$0.28
AU$1.26
+340.7%
65.9%AU$2.88AU$0.55n/a5
Aug ’24AU$0.31
AU$1.26
+305.2%
65.9%AU$2.88AU$0.55n/a5
Jul ’24AU$0.32
AU$1.25
+295.6%
66.3%AU$2.88AU$0.60AU$0.315
Jun ’24AU$0.30
AU$1.27
+322.7%
64.5%AU$2.88AU$0.60AU$0.455
May ’24AU$0.26
AU$1.33
+410.8%
60.5%AU$2.88AU$0.60AU$0.425
Apr ’24AU$0.26
AU$1.15
+343.1%
41.0%AU$2.00AU$0.60AU$0.385
Mar ’24AU$0.23
AU$1.15
+390.2%
41.0%AU$2.00AU$0.60AU$0.355
Feb ’24AU$0.28
AU$1.17
+318.6%
39.9%AU$2.00AU$0.60AU$0.345
Jan ’24AU$0.28
AU$1.15
+318.9%
41.0%AU$2.00AU$0.60AU$0.345
Dec ’23AU$0.36
AU$1.15
+220.0%
41.0%AU$2.00AU$0.60AU$0.305
Nov ’23AU$0.28
AU$1.16
+307.7%
39.7%AU$2.00AU$0.65AU$0.325
Oct ’23AU$0.24
AU$1.16
+374.3%
39.7%AU$2.00AU$0.65AU$0.285
Sep ’23AU$0.28
AU$1.25
+352.7%
40.0%AU$2.00AU$0.65AU$0.284
Aug ’23AU$0.34
AU$1.25
+271.6%
40.0%AU$2.00AU$0.65AU$0.314
Jul ’23AU$0.31
AU$1.25
+301.6%
40.0%AU$2.00AU$0.65AU$0.324

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.